May 23, 2023, Intra-Cellular Therapies Inc. (NASDAQ: ITCI) trading session started at the price of $62.59, that was -1.29% drop from the session before. During the day, the shares moved up to $63.89 and dropped to $61.415 before settling in for the closing price of $62.64. A 52-week range for ITCI has been $42.01 – $66.56.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 299.50%. When this article was written, the company’s average yearly earnings per share was at 22.10%. With a float of $92.23 million, this company’s outstanding shares have now reached $95.14 million.
Let’s determine the extent of company efficiency that accounts for 561 employees. In terms of profitability, gross margin is +91.83, operating margin of -105.32, and the pretax margin is -102.37.
Intra-Cellular Therapies Inc. (ITCI) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Intra-Cellular Therapies Inc. stocks. The insider ownership of Intra-Cellular Therapies Inc. is 0.10%, while institutional ownership is 94.50%. The most recent insider transaction that took place on Apr 17, was worth 630,000. In this transaction Director of this company sold 10,000 shares at a rate of $63.00, taking the stock ownership to the 9,345 shares. Before that another transaction happened on Mar 28, when Company’s EVP, Chief Commercial Officer sold 15,604 for $54.31, making the entire transaction worth $847,380. This insider now owns 45,339 shares in total.
Intra-Cellular Therapies Inc. (ITCI) Recent Fiscal highlights
Going through the last 3-months fiscal report unveiled on the 3/30/2023, it has been observed that the corporation posted -$0.46 earnings per share (EPS) during the time that was better than consensus figure (set at -$0.61) by $0.15. This company achieved a net margin of -102.37 while generating a return on equity of -47.72. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.61 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 22.10% per share during the next fiscal year.
Intra-Cellular Therapies Inc. (NASDAQ: ITCI) Trading Performance Indicators
You can see what Intra-Cellular Therapies Inc. (ITCI) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 8.50. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 19.27.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.41, a number that is poised to hit -0.60 in the next quarter and is forecasted to reach -0.62 in one year’s time.
Technical Analysis of Intra-Cellular Therapies Inc. (ITCI)
Looking closely at Intra-Cellular Therapies Inc. (NASDAQ: ITCI), its last 5-days average volume was 0.68 million, which is a drop from its year-to-date volume of 0.8 million. As of the previous 9 days, the stock’s Stochastic %D was 11.73%. Additionally, its Average True Range was 2.05.
During the past 100 days, Intra-Cellular Therapies Inc.’s (ITCI) raw stochastic average was set at 80.73%, which indicates a significant increase from 26.09% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 28.74% in the past 14 days, which was lower than the 42.30% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $58.05, while its 200-day Moving Average is $51.66. However, in the short run, Intra-Cellular Therapies Inc.’s stock first resistance to watch stands at $63.34. Second resistance stands at $64.85. The third major resistance level sits at $65.82. If the price goes on to break the first support level at $60.87, it is likely to go to the next support level at $59.90. Now, if the price goes above the second support level, the third support stands at $58.39.
Intra-Cellular Therapies Inc. (NASDAQ: ITCI) Key Stats
There are 95,926K outstanding shares of the company, which has a market capitalization of 5.98 billion. As of now, sales total 250,310 K while income totals -256,260 K. Its latest quarter income was 95,310 K while its last quarter net income were -44,050 K.
